New pill takes aim at hard-to-treat cancers with HER2 mutations
NCT ID NCT07361562
First seen Jan 28, 2026 · Last updated May 12, 2026 · Updated 18 times
Summary
This early-phase study tests a new oral drug, CGT4255, in about 100 adults whose advanced solid tumors have certain genetic changes (ERBB2 alterations or HER2 overexpression). The main goals are to check the drug's safety, find the best dose, and see if it shrinks tumors, including in the brain. Participants must have cancers like breast or lung cancer that have not responded to other treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
NEXT Oncology Texas
RECRUITINGAustin, Texas, 78758, United States
-
NEXT Oncology Virginia
RECRUITINGFairfax, Virginia, 22031, United States
-
NYU Langone
RECRUITINGNew York, New York, 10016, United States
-
START Midwest
RECRUITINGGrand Rapids, Michigan, 49546, United States
-
START Mountain Region
RECRUITINGWest Valley City, Utah, 84119, United States
-
Tennessee Oncology
RECRUITINGNashville, Tennessee, 37203, United States
Conditions
Explore the condition pages connected to this study.